Earnings call
Jagsonpal Pharmaceuticals Q3 FY26 earnings call: The industry is expected to grow around 7.5% to 8.5%, and Jagsonpal Pharmaceuticals Limited is expecting upward of 10% in the current quarter
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The industry is expected to grow around 7.5% to 8.5%, and Jagsonpal Pharmaceuticals Limited is expecting upward of 10% in the current quarter. Nine-month top line grew 6%, driving a 13% bottom-line improvement, while its RPM grew 3% to 3.5% as some segments went through inherent cyclicity. The Indian pharmaceutical market (IPM) grew about 8%, largely driven by price growth of 5% to 5.5%, while volume growth stayed muted. Roughly 35% to 40% of Jagsonpal Pharmaceuticals Limited’s portfolio is acute, with the remainder semi-chronic.
The numbers management gave
Results
- Nine-month top line grew 6%, driving a 13% bottom-line improvement, while its RPM grew 3% to 3.5% as some segments went through inherent cyclicity.
Show source
While the performance in the last two quarters reflected temporary pause in our momentum due to certain transitional factors, such as GST, which got changed in Q2, and our own improvement initiatives in Q3, on a nine-month basis or a year-to-date basis, we had a resilient performance with 6% growth in top line, driving a 13% bottom line improvement.
- Revenue was INR 73 crores, EBITDA was INR 16.7 crores and EBITDA margin was 22.7% in Q3 FY26.
Show source
Our third quarter performance remained largely flattish, with revenue at INR 73 crores.
- PAT grew 10% year-on-year to INR12.5 crores, and PAT margin improved by 180 bps to 17.1% in Q3 FY26.
Show source
PAT grew by 10% year-on-year to INR12.5 crores, with PAT margins Page 3 of 13 Jagsonpal Pharmaceuticals Limited January 22, 2026 improving by 180 bps to 17.1%, reflecting the company's operational resilience and underlying brand strength.
- Nine-month revenue grew 6% year-on-year to INR223 crores, while EBITDA increased 5% year-on-year to INR50.3 crores, with margins at 22.6%.
Show source
For the nine-month period, performance remained healthy, with revenue growing 6% year-on- year to INR223 crores, while EBITDA increased by 5% year-on-year to INR50.3 crores, with margins at 22.6%.
- Nine-month PAT was INR 35.9 crores, up 12.5% year-on-year, with margins at 16.1%.
Show source
PAT for the period stood at INR 35.9 crores, reflecting a 12.5% year-on-year growth, with margins at 16.1%.
- The company provided INR2.1 crores as an exceptional item during the quarter for additional past service cost based on its initial estimation of the new labour code.
Show source
Coming to new labour code, based on initial estimation, we have provided for an additional past service cost of INR2.1 crores as an exceptional item during the quarter.
Show 1 more statement
Money and capital
- Free cash balance stood at INR176 crores, an increase of INR15.2 crores in the quarter.
Show source
Our free cash balance now stands at INR176 crores, reflecting an increase of INR15.2 crores in the quarter, again reflecting our strong operational discipline.
What it expects ahead
What management expects
- The industry is expected to grow around 7.5% to 8.5%, and Jagsonpal Pharmaceuticals Limited is expecting upward of 10% in the current quarter.
Show source
We are expecting upward of 10% in the current quarter.
- Short-term aim is to achieve growth 50% more than the industry growth.
Show source
Our idea, Sajal, at least what I am aiming in the short term is 50% more than the industry growth.
- The company expects growth acceleration to double digits from Q4 itself.
Show source
As I mentioned earlier, we are confident of a growth acceleration to double digits from Q4 itself.
- The company expects to increase volume growth and contribution from new products going forward. Replaced by a later filing.
Show source
We expect that we will be able to increase our volume growth going forward as well as contribution from the new products.
What it is building and selling
Demand and pricing
- The Indian pharmaceutical market (IPM) grew about 8%, largely driven by price growth of 5% to 5.5%, while volume growth stayed muted.
Show source
At an industry level, the IPM grew at about 8%, largely driven by price growth of 5% to 5.5%, even as the volume growth stayed muted.
- More than 50% of Jagsonpal Pharmaceuticals Limited’s growth comes from price, with the balance coming from volume and new products.
Show source
But it is in the similar lines as the industry has, which is more than 50% of the growth is coming with the price.
- The industry’s volume growth in recent quarters was very low single digit, about 1%, 1.5% or at most 2%.
Show source
So, if you look at the recent past of maybe three or four quarters, you will find that the volume is hardly to a very, very low single digit, either 1%, 1.5% or maximum 2%.
- Amrut Medhekar said government purchases are increasing and are mostly of brands eating into the private practice market.
Show source
One is there is a good amount of government spending and therefore a lot of government purchases are happening, which is mostly of the brands which are eating into the private practice market.
- Amrut Medhekar said prescriptions for combination brands are increasing, reducing the number of brands per prescription.
Show source
And also there is a theory that combination brands, prescription from the doctors are increasing and thereby per prescription number of brands are getting reduced.
- Amrut Medhekar said generics are growing equally as branded pharma. Replaced by a later filing.
Show source
Secondly, the generics are also growing equally as the branded pharma, right?
Show 1 more statement
Segments
- Roughly 35% to 40% of Jagsonpal Pharmaceuticals Limited’s portfolio is acute, with the remainder semi-chronic.
Show source
So, we have a typical mix of roughly around 35% to 40% of acute and remaining is into semi-chronic.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Deepesh J Sancheti: How do you think on an overall basis on how pharma companies will be taking this new labour code and how has it affected Jagsonpal, I mean, going forward?
Answer, manish gupta
Manish Gupta: I don't think we can comment on how other companies will be taking it. Dipesh Sancheti: Overall in the form of business.
Answer, manish gupta
Manish Gupta: I don't think it will be very different from how we have handled it. Clearly, there are guidelines around it. It is effective from 21st November, but the state rules of notifications are yet to happen. There will be some restructuring of salaries involved at all levels. But having said that, there will be some one-time hit as we have taken. Similar things will be probably applicable for most of the company. But, I mean, that's my general feeling.
Answer, manish gupta
I don't want to speak on behalf of other companies. I personally welcome this move. It kind of puts up a common framework across all the setups and is a good move in the form of balancing the labour interest and the industry interest.
Question
Deepesh J Sancheti: Okay. So, will there be any salesforce rationalizations to be considered?
Answer, amrut medhekar
Amrut Medhekar: No, no, there won't be any. This is Amrut. There won't be any rationalization on the field or at HO. Deepesh J Sancheti: Okay. Now, my second question is regarding the growth. I mean, firstly, is the management really happy with the 6% growth? And going forward, where do you see this?
Answer, amrut medhekar
Amrut Medhekar: It's a mixed bag of performance. Obviously, as Manish has said in his opening remarks, the growth is not as per our own expectations. So, there's a lot of scope for improvement for us to do. And that's what we are on the job to do that. Page 4 of 13 Jagsonpal Pharmaceuticals Limited January 22, 2026 However, if you're asking in terms of breakup of the growth, then some of the brands have certainly outperformed the market, while some of the brands are lagging. So, that's where we are working. And hopefully, we'll be able to beat the market growth as soon as possible.
Question
Deepesh J Sancheti: So, will that affect our sales mix going forward? As in, are we planning just to correlate this data and try to get a better sales mix going forward for these brands which are performing well? Is that going to happen or we are going to explore the market as it is?
Answer, amrut medhekar
Amrut Medhekar: Obviously, sales mix is primarily what the organization wants and where the need lies in the market. So, that gap is where we are trying to fit in. And if that means that it will change our gross margins, no, it won't.
Question
Deepesh J Sancheti: So, along with that, what will be the sales, I mean, what will be the growth drivers for the company going forward for the next one to two years?
Answer, amrut medhekar
Amrut Medhekar: So, the mix will largely remain as to how the India Pharma has been behaving. So, 50% of the growth we are expecting with the price increase as well as on new product and new SKU introductions. And remaining will be the volume growth.
Question
Neelam Punjabi: Thanks for the opportunity. My first question is on the expense of the new, on account of the new labor code. So, is this INR2.1 crores a burn off expense or going forward, would this impact the employee costs that we have on a recurring basis?
Answer, amrut medhekar
Amrut Medhekar: Yes, Neelam, there are two elements to this. The impact has started from 21st of November and yet the notifications from the respective state governments is yet to happen. We expect, or what we at least read in the media, that the revert from the state governments is only expected in the coming month, which is February. So, we expect that the notification should happen early March or end of March. And therefore, the applicability will start from the 1st of April, essentially. However, we have provided for this code, currently one time of INR 2.1 crores. And going forward, there is a very little impact in terms of the overall cost increase for the employee remuneration.
Answer, manish gupta
Manish Gupta: And Neelam, if I may just add, basically if you see the code, there are two elements which impact. One is gratuity, the way gratuity is calculated, and the way leave encashments are calculated. So, this INR 2.1 crores, because gratuity is relating to past many years of service, and leave encashment again is linked to how much, based on company policy, how many leaves you can carry forward based on years of service. Page 5 of 13 Jagsonpal Pharmaceuticals Limited January 22, 2026 Therefore, this is a cumulative impact of the past. And hence, it is shown as one time and exceptional as per the institute guidelines. And as Amrut has clarified, ongoingly there is very limited impact.
Question
Neelam Punjabi: Understood, sir. This was very helpful. My second question is on overall growth of the company. So, in the past, we have highlighted that Jagsonpal’s portfolio should have a steady 12% to 14% kind of organic growth going forward. So, while we understand that in the near term, this has been recalibrated and rejigged our portfolio. So, going forward, are we sticking to this long-term three to four year outlook of 12% to 14% organic growth?
Answer, amrut medhekar
Amrut Medhekar: Yes, Neelam. So, this is what we are looking at , if there are no any macro changes or external changes happening, we expect the growth to be into double digits.
Question
Neelam Punjabi: Got it. Okay. Thank you. And another question is on Yash Pharma. So, if you could just comment on how has the acquisition played out? How has the brands of Yash Pharma played out since our acquisition? Are we happy with the progress?
Answer, amrut medhekar
Amrut Medhekar: We are essentially looking at the past two years since the acquisition has happened. The team has really worked very hard. And today, it is contributing more than the expected lines towards the growth. And also, we are looking at future further expansion of the portfolio into the speciality mix.
Question
Aditya Chheda: Good evening. Can you please break your growth within price, volume, and new product launch for Q3 and nine-months both? And if you have any rough mix that you can share between chronic, sub chronic, and with your portfolio, that would be helpful. Thanks.
Answer, amrut medhekar
Amrut Medhekar: So, Aditya, thanks for your question. However, off the hand, I don't have this breakup exactly. But it is in the similar lines as the industry has, which is more than 50% of the growth is coming with the price. And the balance is coming from the volume and the new products. That's where we are. So, we are no different from the industry growth currently. We expect that we will be able to increase our volume growth going forward as well as contribution from the new products.
Question
Aditya Chheda: The mix of chronic, sub chronic, and acute within the portfolio.
Answer, amrut medhekar
Amrut Medhekar: See, we are not into “very long” chronic therapy. Typically nowadays, the industry is having three segments. So, you have chronic, semi-chronic, and acute. So, we have a typical mix of roughly around 35% to 40% of acute and remaining is into semi-chronic. Page 6 of 13 Jagsonpal Pharmaceuticals Limited January 22, 2026 Aditya Chheda: Got it.
Question
And we have reported a minus [Inaudible 0:17:56] growth for Q3. This implies that it should not be driven by Q3.
Answer, manish gupta
Manish Gupta: Aditya, your line has suddenly turned bad. Can you repeat the question?
Show 16 more questions
Question
Aditya Chheda: Yes. Since we have reported a minus 1 odd percent growth for Q3, this should be all a function of lower volume growth led by the temporary rejig that the organization is going through. If you can advise more details about the nature of this rejig and what exactly was the exercise about, it would be helpful to better appreciate the three numbers.
Answer, amrut medhekar
Amrut Medhekar: Aditya, I will put it into two lenses. One its is not a rejig, I will call it, but it is more of a resource reallocation for better optimization of the resources. Number two, in terms of growth element, since it is minus 1, you can understand it is a miniscule degrowth. We are kind of flattish. This has also been corroborated with the fact that there was some adjustment post-GST rationalization, which is a great move by the government. And third is we were also looking at, in terms of strategically, whether we can reposition some of our brands, so that we are able to drive better growth in the coming quarters.
Question
Sajal Kapoor: Thank you for taking my question. Good afternoon, team. Just a few questions from my side. First of all, hopefully that Q4 growth will be along the lines that we have been hoping and guiding for some time now. Assuming that we mean 10% when we say double-digit, so I am taking the lower end of that range of double-digit. In that 10% assumption, what is our assumed industry growth rate?
Answer, amrut medhekar
Amrut Medhekar: The assumption is currently the industry is growing at roughly around 8%, and I expect Sajal the similar kind of trend to continue. The industry is expected to be around 7.5% to 8.5%. We are expecting upward of 10% in the current quarter. So it is not in the lower end. We hope to be at better with the numbers, Sajal.
Question
Sajal Kapoor: Sure, sure. And do we expect that number to be much more sustainable beyond the Q4?
Answer, amrut medhekar
Amrut Medhekar: 100%, even better. Our idea, Sajal, at least what I am aiming in the short term is 50% more than the industry growth.
Question
Sajal Kapoor: Okay, understood, understood. Thank you for that. And what is our current confidence, Amrut and Manish, in terms of this much-needed improvement in the per capita or the field force productivity? Because we have been grappling with this for a while now. Page 7 of 13 Jagsonpal Pharmaceuticals Limited January 22, 2026 Amrut Medhekar: I understand the pain of this question.
Answer, amrut medhekar
And I think that is the same pain point which we have. But as we grow organically, we are also looking at some product launches which are into high growth territory with a better yield per patient. And hopefully that should happen somewhere at the end of H1 in the coming financial year. And that should add to the volume and value increase, thereby increasing our per capita.
Question
Sajal Kapoor: Sure, sure. And Amrut, on this cash sitting on the books, it's well documented. It keeps increasing every quarter, which is good. 14-15 quarter cash getting added to the balance sheet on a quarterly basis is a fantastic thing for any company, especially given our size, small size. But it's also diluting the ROE, right? So what is the capital allocation thinking going ahead? Are we seriously looking at something?
Answer, manish gupta
Manish Gupta: Yes, Sajal, we are always seriously looking at something. But the capital market is not supportive from an M&A perspective. Obviously, everyone gets much better valuation in the capital market than what a strategic buyer can afford. So clearly, M&A is a very strong intent at our end, but a disciplined M&A which is accretive for our shareholders and not dilutive. So that's very, very important for us. Market has not been supportive in terms of cost or price of acquisition. We did one, Yash Pharma, and have successfully demonstrated our ability to create value out of it.
Answer, manish gupta
We continue to be on a lookout, but we cannot put in a time frame to it. Having said that, if we are unable to use our cash efficiently, we would rather return it to the shareholders in the right format.
Question
Sajal Kapoor: Yes, sure. And finally, a quick book-keeping question for Nirav, perhaps. Depreciation has moved up significantly since March of 2024. The gross block has also significantly increased. Now, please can you refresh my memory in terms of what's driving this depreciation in a business that is largely asset-light with all the manufacturing being outsourced? Thank you.
Answer, nirav vora
Nirav Vora: Yes, that's correct. Depreciation has largely moved up because of, if you would have seen our balance sheet, there is an acquisition which we had done last year, Yash Pharma, and the assets are largely comprised of intangibles, trademarks and all. And because of that, those are getting depreciated over the period, and hence the depreciation line has gone.
Question
Sajal Kapoor: Right, so that's purely because of Yash Pharma and the intangibles, not the manufacturing assets?
Answer, nirav vora
Nirav Vora: No, no. So we do not have a very large base of tangible assets. It's very small. The largest portion lies in the intangible assets.
Answer, manish gupta
Manish Gupta: Our tangible assets are only net profits.
Question
Sajal Kapoor: Yes, yes. Okay, thank you.
Answer, manish gupta
Manish Gupta: Not only it helps that, but also helps our fixed planning in a way. Page 8 of 13 Jagsonpal Pharmaceuticals Limited January 22, 2026 Sajal Kapoor: Yes, yes, of course, Manish.
Question
Thank you for all the responses. Fingers crossed. We look forward to a much positive Q4. Thank you.
Answer, manish gupta
Manish Gupta: Thank you, Sajal, for your positive pressure.
Question
Pulavarthi Saikiran: Yes. I'm just wondering, sir, if you always mention that cash is a successful acquisition. Just curious from your perspective, how do you define this success in terms of acquisition? What are the parameters based on which you evaluate on the hindsight basis this is a successful acquisition?
Answer, manish gupta
Manish Gupta: Let me respond my way and then Amrut can add from a business perspective. But looking at an investment lens, A, the business is among the fastest-growing business within our portfolio. B, the margins, which were about half of Jagsonpal Pharma at the time of acquisition, have been already aligned with our overall corporate margins. C, the business practices or the cash flow generation out of that business is also fully aligned with our own business. And finally, of course, the ROI or the price that we invested in, we certainly have more than double-digit returns on our investments within the first year. So, these were the three or four criterias we used to justify this acquisition from a brand or any perspective if we wish to. Of course, one more strategic angle I would give is, it probably added are two therapeutic areas because JPL had very limited RPM.
Answer, manish gupta
And that helped us expand our RPM and provide us additional growth engines.
Question
Pulavarthi Saikiran: Understood, sir. Sir, my second question is that in terms of one of the earlier participants' questions, you mentioned in terms of the capital allocation. One is an M&A or you also mentioned that if you can't find anything, you will prefer or rather you will find a way to return to the shareholders. Do you foresee any other way of putting the cash to work to expand the existing business organically? I do understand that you follow the asset light model, but do you foresee a scenario where you would like to put some cash to work in terms of expanding the distribution or maybe adding a few more therapeutic areas? Is that something which you would like to consider?
Answer, manish gupta
Manish Gupta: Absolutely, that is part of the agenda, but clearly our kind of business does not require that kind of cash. So, while we will put some capital to risk in terms of additional growth engines within our portfolio, but the kind of cash generation we have, unless it is used for M&A and M&A can Page 9 of 13 Jagsonpal Pharmaceuticals Limited January 22, 2026 take multiple shapes. It can be a brand acquisition, business acquisition and or a company acquisition. But come what may, I don't think we can burn cash disproportionately given the way we run. Amrut, if you would like to add.
Answer, amrut medhekar
Amrut Medhekar: Yes, I mean both the options are on the table. So, we will obviously deploy capital in the most meaningful way which is EBITDA accretive eventually. And also, we are seriously looking at some of the good acquisition candidates. Currently, the assets are very highly priced. So, we are looking at something which will bring value to the shareholders.
Question
Pulavarthi Saikiran: Thank you. Thank you very much. Really appreciate it. Thank you very much.
Answer, amrut medhekar
Amrut Medhekar: I have not understood your question completely. But if you are asking me what are the leading or lagging indicators for the market, I would say that… Pushkar: Like market share erosion. If there is some brand which is -- there are early signs of market share erosion in that specific brand. What are the leading indicators that we monitor?
Answer, amrut medhekar
Amrut Medhekar: One would be, of course, what we get in terms of the market research reports, which are kind of custom built for the organization many a times. And then there are subscription models which are also available, which we do, and which will be early indicators for us. However, the report only comes post hoc. It is a stockist out data which gets released maybe a week after the month ends. But that gives a guiding idea in terms of where the market is heading. Pushkar: Right, right. So, and then if there is a market share loss in some of the brands, then there are like corrective actions or maybe, incentives to sales force, etc. Amrut Medhekar: Correct.
Question
Kriya Shah: So, I just wanted to ask you what is the current [Inaudible 0:31:19] productivity and how do you plan to further increase your [Inaudible 0:31:23]?
Answer, manish gupta
Manish Gupta: You will have to repeat the question. We can't hear you at all.
Question
Kriya Shah: Sorry. What is the current MR productivity and how do you plan to further increase the doctors per brand and brands per doctor? Page 10 of 13 Jagsonpal Pharmaceuticals Limited January 22, 2026 Amrut Medhekar: So, I will choose two answers to the two-pronged question.
Answer, amrut medhekar
In terms of productivity, we are little less than our peer group which we are trying to build up. And once we reach there, actually our growth will be automatically driven towards higher double digits which we are trying to do. Second piece is obviously this growth has to come from two ways. Either we increase our prescriber base or we increase P/D which is prescription per doctor whether it is in terms of absolute number of prescription increasing for one individual brand or number of brands increasing per doctor. So, we are working on both the pyramids and hope to see that the picture turns deep green soon enough.
Question
Aditya Chheda: Hi. So, apart from the internal calibration, would you attribute any other reasons for growth lower than your earlier expectations in FY ‘26?
Answer, amrut medhekar
Amrut Medhekar: Aditya, I think the industry itself is kind of flattish other than the new products and the price growth, it has been muted. So, if you look at the recent past of maybe three or four quarters, you will find that the volume is hardly to a very, very low single digit, either 1%, 1.5% or maximum 2%. Even the recent report is alluding to the same. So, I think there are two kinds of shifts which are happening, which I am making an assumption here. One is there is a good amount of government spending and therefore a lot of government purchases are happening, which is mostly of the brands which are eating into the private practice market. Secondly, the generics are also growing equally as the branded pharma, right? And also there is a theory that combination brands, prescription from the doctors are increasing and thereby per prescription number of brands are getting reduced.
Answer, amrut medhekar
So, doctors are prescribing more of combination brands and this I am alluding to you with the data point. So, combination brands are increasing in India vis a vis a single molecule prescription. So, therefore, the volume growth looks muted.
Question
Aditya Chheda: Okay, sir. That was helpful.
Answer, manish gupta
Manish Gupta: Dheeresh, I think Amrut would like, I mean, we have two consecutive quarters of slow growth. One was certainly impacted by GST as I covered in my opening remarks. And the second one, again, or the current one, has been lower than expectations, our own worst expectations, partly driven by, again, internal factors because we have, I mean, with Amrut joining us, he has initiated certain critical actions which are going to be, which, I mean, kind of impacted growth for short- Page 11 of 13 Jagsonpal Pharmaceuticals Limited January 22, 2026 term but with a long-term intent of course correcting in terms of driving long-term growth. But anything you would like to add?
Answer, amrut medhekar
Amrut Medhekar: Yes, I think, I mean, Manish has already covered those two points. So, we are looking at more of strategic alignment towards our strength. And there is also kind of resource reallocation of the product, the brand priority as well as the people priority. Dheeresh: Yes, so, just if you can just maybe, just simplify it. So, have you let go of some long-tail brands? And GST also, we are not seeing it in at least, not all companies are reported yet. But the companies that are reported this quarter, like we are seeing good reported growth.
Answer, amrut medhekar
So, GST is our distribution very different from the distribution of other large pharma companies because we are not seeing, at least for the companies that are reported, the slowdown being attributed to GST. So, both the two things, if you can clarify.
Answer, amrut medhekar
Amrut Medhekar: I have not seen those reports so far, the two reports which have come out. Possibly, I will read much in detail. But frankly speaking, there had been an inventory correction in the market at the time of GST implementation. And thereby, the primary sales have certainly got impacted. However, for us as well as the industry, I don't think much of secondary got impacted or the tertiary demand got impacted. So, there had been this temporary pause, I will say in terms of growth momentum, which was there. But as Manish had said in the opening remark, that this is already behind for the industry and things are normalized from the last quarter.
Answer, amrut medhekar
And hopefully, from this quarter, you will see a good growth happening for the business. Dheeresh: And what do you mean when you say restructuring? So, there are certain tail brands that you have let go off or what exactly has, if you can just elaborate on what you have done?
Questions about this call
- When was the Jagsonpal Pharmaceuticals Q3 FY26 earnings call transcript filed?
- Jagsonpal Pharmaceuticals filed the transcript with the exchange on 27 Jan 2026. This page is built from that transcript.
- What does this page list?
- 18 statements from the transcript across 5 topics, 11 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 26 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.